Researchers in Oman studied 21 epileptic children receiving 25-114 mg/kg of vigabatrin daily. The average duration of drug treatment was nearly 36 months (with a range of 6-85 months).

Among these children, four developed eye changes, including retinal pigmentation, hypopigmented retinal spots and optic nerve damage. The investigators also observed abnormal vision in 16 of the children.

The researchers warn that, based on their findings, physicians should carefully weigh the risks and benefits before prescribing vigabatrin, and that patients should have regular eye examinations and tests every three to six months (Arch Dis Child, 2001; 85: 469-73).